Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) gapped up before the market opened on Friday .The stock had previously closed at $17.69, but opened at $18.18. Spyre ...

WALTHAM, Mass., March 7, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing ...

WALTHAM, Mass., March 27, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing ...

Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com .

Preclinical data demonstrates that SPY003 is highly potent and has potential for quarterly or biannual dosing, suggesting opportunity for improved efficacy and convenience over first-generation ...

Wolfe Research initiated coverage of Spyre Therapeutics (SYRE) with an Outperform rating and $27 price target The company is an early stage biotech with Phase 1 readouts in 2025, offering a ...

Spyre Therapeutics has a 52 week low of $17.24 and a 52 week high of $47.97. The business’s fifty day simple moving average is $21.65 and its 200-day simple moving average is $26.41.

Investors considering a purchase of Spyre Therapeutics Inc (Symbol: SYRE) stock, but cautious about paying the going market price of $18.16/share, might benefit from considering selling puts among ...